CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
This is a single center, single arm, open-label phase 1 study to determine the safety and efficacy of autologous T cells expressing CD19 chimeric antigen receptors in adults with CD19+ B cell malignancies.
B-cell Malignancy|B-cell Lymphoma|B-Cell Acute Lymphoblastic Leukaemia
BIOLOGICAL: CD19 CAR T
Frequency and severity of toxicities and adverse events, To assess the frequency and severity of toxicities and adverse events according to NCI CTC v4.0, 24 weeks
overall response rate, To assess the overall response rate after CD19 CAR T infusion in R/R B cell malignancies, 24 week|overall survival, To assess the overall survival in patients with R/R B cell malignancies, 24 week
This is a single-center, Open Label phase I clinical trial, 9 subjects planned to be enrolled. The subjects will be divided into low-dose group, medium-dose group and high-dose group.Dose CAR+ cells/kg Low 1×105 Medium 2×106 High 6×106